ClinicalTrials.gg
RecruitingNCT06969729Updated Apr 16, 2026

Evaluation of Clinical Efficacy and Safety of Aortal Stent-Graft Created Using 3D Printing Technology

An interventional study of Physician-Modified Fenestrated Stent-Graft (3D-Printed Template-Guided) in Abdominal Aortic Aneurysm, Juxtarenal Abdominal Aortic Aneurysm and Pararenal Abdominal Aortic Aneurysm, sponsored by Samodzielny Publiczny Szpital Kliniczny nr 2 PUM. Recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-16.

Primary conditionAortic Aneurysm, ThoracoabdominalRegistry: Aortic Aneurysm, AbdominalReclassifiedWhy we changed it
Registry
Aortic Aneurysm, Abdominal — the first condition term the registry derived for this study.
ClinicalTrials.gg
Aortic Aneurysm, Thoracoabdominal
Why
  1. The study's listed conditions name Aortic Aneurysm, Thoracoabdominal, a narrower term within Aortic Aneurysm, Abdominal.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Samodzielny Publiczny Szpital Kliniczny nr 2 PUM · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

the comparison of physician-modified stent-graft created in 3D models versus custom-made devices in the treatment of complex abdominal aortic aneurysm

Read the detailed description

This is randomized, multicenter, open-label, 2 -arm Study to evaluate the efficacy and safety in stent-graft application of arm A and Arm B in patients with juxtarenal or pararenal abdominal aortic aneurysm, thoracic-abdominal aneurysm type IV or type IA endoleak.

Approximately 100 eligible patients will be randomized in a 1:1 ratio into 2 arms (n=50 in each arm) Arm A treated with innovative angiosurgery intervention Arm B standard procedure Study will use an Interactive Web Response System (IWRS) for randomization. Randomization will be used to minimize bias in the assignment of subjects to treatment groups, to increase the likelihood that known and unknown subject attributes (e.g. demographic and baseline characteristics) are evenly balanced, and to enhance the validity of statistical comparisons across treatment groups.

Subjects will be randomized based on following stratification: • Site

  • Aneurysm class Subject participation will include a Screening Phase, Intervention Phase, Safety follow-up and End of Study.

The screening phase will last up to 28 days before the therapeutic intervention periods starts (two hospitalizations finished with 2 angio surgery intervention) during which the subject's eligibility and baseline characteristics will be determined. The therapeutic intervention will last from randomization until second hospitalization will end with angio surgery intervention). There will be 2 follow up visits. Safety follow up will lasts 12 months.

Aorta assessment by angio CT will be performed at screening, intervention period at hospitalization no. 1 and in 30 day follow up, 12 month follow up

02

Conditions studied

  • Abdominal Aortic Aneurysm
  • Juxtarenal Abdominal Aortic Aneurysm
  • Pararenal Abdominal Aortic Aneurysm
  • Thoracoabdominal Aortic Aneurysm
  • Type IA Endoleak

Browse trials for

Keywords

  • AAA
  • physician-modified stent-graft
  • custom-made device
  • complex abdominal aortic aneurysm
  • juxtarenal abdominal aortic aneurysm
  • pararenal abdominal aortic aneurysm
  • thoracoabdominal aortic aneurysm
  • endovascular aneurysm repair
  • 3D printing
  • 3D model
  • PMEG
  • type IA endoleak
  • aortic stent-graft
  • PMSG
  • patient-specific 3D model
  • complex aortic pathology
03

In context

Aortic Aneurysm, Thoracoabdominal Reclassified

63 studies on the registry are indexed under Aortic Aneurysm, Thoracoabdominal; 31 are open to participants now.

This study's planned enrollment of 100 is above the median of 80 across 41 interventional studies indexed under Aortic Aneurysm, Thoracoabdominal.

Browse Aortic Aneurysm, Thoracoabdominal studies →

Lead sponsor

Samodzielny Publiczny Szpital Kliniczny nr 2 PUM is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Compared within Aortic Aneurysm, Thoracoabdominal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Aortic Aneurysm, Abdominal. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Female and male subjects age ≥ 18 2. Subject need to meet one of the following criteria:

  • Subjects with juxtarenal or suprarenal abdominal aortic aneurysm, type IV thoracoabdominal aneurysm of diameter >5.5cm (male) and 5.2cm (female)
  • Subjects with juxtarenal or suprarenal abdominal aortic aneurysm, type IV thoraco-abdominal aneurysm with aneurysm growth rate ≥ 0.5cm during 6 months
  • Type IA endoleak of post-implantation of abdominal stent- graft 3. Iliac arteries morphology with aortic stent graft implantation to be restored 4. Aortic segment which is proximal to aneurysm
  • Length ≥20mm
  • Diameter 20mm-36mm
  • Aortic suprarenal angle ≤75 degrees 5. Survival > 2 years

Exclusion criteria

Exclusion Criteria:

  1. Female and male subjects age \<18
  2. Pregnancy and breast feeding
  3. Allergy and to matherials of which the stent- graft is composed
  4. Hypersensitivity and to anti coagulation or contrast application to angio - CT which cannot be eliminated medically
  5. Coagulopathy which cannot medically treated
  6. Active infection which might cause stent - graft infection
  7. Creatinine level > 3.0mg/dL
  8. Marphan syndrome, Ehlers - Denlos syndrome
  9. Unstable angina pectoris
  10. Raptured aortic aneurysm caused by cardiac insufficiency
  11. Unwillingness to comply with protocol procedures
  12. Iliac arteries morphology adequate for stent-graft implantation
  13. The diameter of the aortic flow lumen in reno-visceral aorta greater than 34mm
  14. Aortic section which is proximal to celiac artery with significant number of thrombi, calcification or changed by aneurysm
  15. Aorta with significant number of irregular thrombi which may lead to embolism ("shaggy aorta")
  16. Diameter of proximal kidney arteries which is exercisable to stenting \<4.5mm
  17. Devision of kidney artery which is exercisable to stenting in the distance of \<1cm of celiac artery, each of them is is in \<4.5mm in diameter
  18. Atypical anatomy of celiac artery in the form of separate exit of splenic and hepatic aortic artery
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Physician-Modified Stent-Grafts Made Using 3D Aortic Template

    Patients with aortic pathology undergoing implantation of physician-modified stent-grafts created using a patient-specific 3D-printed aortic template.

    Procedure: Physician-Modified Fenestrated Stent-Graft (3D-Printed Template-Guided)

  • Active comparator
    Custom-Made Fenestrated Stent-Graft

    Implantation of a commercially manufactured, patient-specific custom-made fenestrated stent-graft via an endovascular approach.

    Procedure: Physician-Modified Fenestrated Stent-Graft (3D-Printed Template-Guided)

Interventions

  • ProcedurePhysician-Modified Fenestrated Stent-Graft (3D-Printed Template-Guided)

    Implantation of a physician-modified fenestrated stent-graft using a patient-specific 3D-printed aortic template, performed via an endovascular approach.

06

What researchers measure

Primary outcomes

  1. Number of Participants Surviving at 1 Year Without Aortic Rupture

    Rupture - free one year survival. The number of participants who remain alive and free from aortic rupture at 1 year following stent-graft implantation. Rupture will be defined as radiologically confirmed loss of aortic wall integrity with associated clinical symptoms.

    Time frame: 1 year

  2. Number of Participants Surviving at 30 Days Post-Procedure (Perioperative Survival)

    The number of participants who are alive 30 days after the stent-graft procedure. Deaths from any cause within 30 days post-implantation will be counted.

    Time frame: 30 days

Secondary outcomes

  1. Number of Deaths from Any Cause Within 1 Year

    Total number of participant deaths due to any cause occurring within one year of the procedure.

    Time frame: 1 year

  2. Number of Cardiovascular-Related Deaths Within 1 Year

    The number of participant deaths attributed to cardiovascular causes (e.g., myocardial infarction, stroke, aortic rupture) within 1 year of the procedure, as adjudicated by the study investigators.

    Time frame: 1 year

  3. Number of Participants Without Aneurysm Growth at 1 Year

    The number of participants whose aneurysm size remains stable (no increase \>5 mm in maximum diameter) as assessed by imaging (e.g., CT angiography) at 1 year post-implantation.

    Time frame: 1 year

  4. Number of Participants Surviving Without Reintervention at 1 Year

    The number of participants who do not require any secondary endovascular or surgical intervention related to the index aortic pathology within 1 year of the initial procedure.

    Time frame: 1 year

  5. Change in Incidence of Cardiovascular Events at 1 Year

    Change in the number of participants experiencing cardiovascular events (e.g., myocardial infarction, stroke, cardiac arrest) compared to baseline rates or historical controls over a 1-year follow-up period.

    Time frame: 1 year

  6. Number of Deaths from Any Cause at 1 Year (Overall Mortality)

    The total number of participant deaths from any cause within one year of the stent-graft procedure.

    Time frame: 1 year

  7. Change in Renal Function at 1 Year

    Change in estimated glomerular filtration rate (eGFR) or serum creatinine level from baseline to 1 year post-procedure, used to assess renal function.

    Time frame: 1 year

  8. Total Cost of Treatment at 1 Year

    Cumulative healthcare cost per participant associated with the initial stent-graft procedure, hospitalization, follow-up visits, imaging, medications, and any reinterventions within 1 year.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • An Independent Clinical Hospital 2 PUM
    Szczecin, West Pomeranian Voivodeship 70-111, Poland
    Recruiting
08

References and documents

Publications

  • Rynio P, Jedrzejczak T, Rybicka A, Milner R, Gutowski P, Kazimierczak A. Initial Experience with Fenestrated Physician-Modified Stent Grafts Using 3D Aortic Templates. J Clin Med. 2022 Apr 13;11(8):2180. doi: 10.3390/jcm11082180. PubMed 35456273 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared due to institutional data governance policies and applicable data protection regulations, including the General Data Protection Regulation (GDPR) and national laws. These frameworks restrict the sharing of detailed clinical data with external parties to ensure the confidentiality and security of participant information.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2022 (actual). Primary completion is estimated for Apr 2027, 53 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2023
First posted
May 14, 2025
StartActual
Nov 1, 2022
Primary completionEst.
Apr 30, 2027
CompletionEst.
Apr 30, 2027
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06969729
Lead sponsor
Samodzielny Publiczny Szpital Kliniczny nr 2 PUM
Responsible party
Sponsor
First posted
May 14, 2025
Start date
Nov 1, 2022
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Apr 16, 2026

Study contacts

Pawel Rynio
Contact
p.rynio@spsk2.szczecin.pl
914661156

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion